His Aib Glu Phe GLP -1R
Research-Grade · USA Domestic · COA Verified

Metabolic Peptide Research

The most researched GLP-1 analogs and metabolic compounds — Semaglutide, Tirzepatide, AOD-9604, and more. Sourced at ≥99% purity from a USA domestic warehouse.

Browse Metabolic Peptides → View Compounds
≥99%
Purity Standard
COA
Every Product
🇺🇸
USA Domestic
FREE
Shipping All Orders
SEMAGLUTIDE · TIRZEPATIDE · AOD-9604 · CJC-1295 · IPAMORELIN · TESAMORELIN · HGH FRAG 176-191 · MELANOTAN II · SEMAGLUTIDE · TIRZEPATIDE · AOD-9604 · CJC-1295 · IPAMORELIN · TESAMORELIN · HGH FRAG 176-191 · MELANOTAN II ·
Research Compounds

Metabolic & Weight Loss Peptides

The following compounds represent the most studied peptides in metabolic and obesity research. All available from QSC Peptides with full COA documentation.

GLP-1 Analog · Weight Research
Semaglutide
GLP-1 Receptor Agonist — Research Grade

Semaglutide is a GLP-1 receptor agonist analog extensively studied for its role in appetite regulation, glucose homeostasis, and metabolic rate modulation. Originally developed for type 2 diabetes research, it has become a central subject in weight management and obesity biology studies. Available in research-grade lyophilized powder form.

GLP-1 Agonist Appetite Research Metabolic Glucose
Source Research-Grade Semaglutide →
Dual GIP/GLP-1 · Metabolic
Tirzepatide
Dual GLP-1/GIP Receptor Agonist

Tirzepatide is a novel dual agonist targeting both GLP-1 and GIP receptors, representing a significant advancement in metabolic peptide research. Studies show its action on two incretin pathways may produce more pronounced effects on weight and metabolic markers than single-receptor agonists. A key research compound for obesity biology.

Dual Agonist GIP + GLP-1 Obesity Research Incretin
Source Research-Grade Tirzepatide →
HGH Fragment · Lipolysis
AOD-9604
hGH Fragment 176-191 Analog

AOD-9604 is a modified fragment of human growth hormone studied for lipolytic (fat-burning) effects without the hyperglycemic or mitogenic side effects of full hGH. Research indicates it stimulates beta-3 adrenergic receptors, reducing fat accumulation in animal models without affecting IGF-1 levels — making it a uniquely selective metabolic research compound.

Lipolysis HGH Fragment Beta-3 Agonist Fat Research
Source AOD-9604 →
GHRH Analog · GH Pulse
CJC-1295 + Ipamorelin
GHRH Analog + GHRP Combination

The CJC-1295/Ipamorelin combination is one of the most studied GH secretagogue stacks in research. CJC-1295 extends half-life of GHRH while Ipamorelin provides clean GH pulse stimulation. Combined research explores effects on body composition, lipolysis, and IGF-1 without significant cortisol or prolactin elevation.

GH Secretagogue GHRH Analog Body Composition IGF-1
Source CJC-1295 / Ipamorelin →
Trusted Supplier

Where Researchers Source These Compounds

QSC Peptides is the recommended US-domestic supplier for all metabolic research peptides listed on this site. Every compound ships with a Certificate of Analysis (COA) verifying ≥99% purity.

Shop Metabolic Peptides at QSC →
🧪

≥99% Purity Guaranteed

HPLC tested · Third-party verified · COA on every order

🇺🇸

USA Domestic Warehouse

USPS/FedEx · 2-5 day delivery · No import delays

🚚

Free Shipping — All Orders

No minimum · Discreet packaging · Tracking included

🌐

Ships Worldwide

EU · UK · Australia · Canada · Asia Warehouse warehouses

→ BROWSE ALL METABOLIC PEPTIDES AT QSC-USA.COM
How It Works

The Science of Metabolic Peptides

01
GLP-1 Receptor Agonism

GLP-1 analogs like Semaglutide work by mimicking the glucagon-like peptide-1 hormone, stimulating insulin secretion and suppressing glucagon. Research shows sustained activation of GLP-1 receptors significantly modulates appetite pathways in the hypothalamus.

02
Lipolysis Pathways

Compounds like AOD-9604 and HGH Fragment 176-191 are studied for their selective activation of beta-3 adrenergic receptors in adipose tissue, which triggers lipolysis (fat breakdown) without affecting blood glucose or IGF-1 signaling — a key distinction from full hGH.

03
GH Pulse Stimulation

GHRH analogs (CJC-1295) and GHRPs (Ipamorelin) work synergistically to amplify natural growth hormone pulses. Research shows this dual stimulation enhances GH secretion with minimal effect on cortisol, making it a valuable tool for studying body composition and metabolic rate.

Common Questions

Frequently Asked Questions

What is the difference between Semaglutide and Tirzepatide? +
Semaglutide targets only the GLP-1 receptor, while Tirzepatide is a dual GLP-1/GIP agonist. In research settings, the dual-agonist mechanism of Tirzepatide may produce distinct metabolic effects. Both are available as research-grade lyophilized peptides from QSC Peptides.
Are these peptides available for research in the USA? +
Yes. Research peptides like Semaglutide, Tirzepatide, and AOD-9604 are available for laboratory and research purposes from domestic US suppliers like QSC Peptides. They are labeled and sold as "Research Use Only" compounds with full COA documentation.
What does COA mean and why does it matter? +
COA stands for Certificate of Analysis. It is a document from a third-party laboratory confirming the identity, purity, and concentration of the compound via HPLC or mass spectrometry. Without a COA, you cannot validate the quality of a research compound. QSC Peptides includes a COA with every product.
How fast does QSC Peptides ship? +
QSC ships from a USA domestic warehouse via USPS and FedEx. Most US orders arrive within 2-5 business days. All orders include free standard shipping with tracking. They also have warehouses in the EU (GLS), Australia, Canada, Singapore, Thailand, Vietnam for international researchers.
Compound Profiles

Metabolic Peptide Research Reference

Detailed profiles on each major metabolic and weight-loss research peptide available via QSC Peptides. All compounds are research-grade, COA-verified, and sold strictly for scientific study.

Semaglutide
GLP-1 Receptor Agonist Analog
TypeGLP-1 RA peptide analog
MW4113.6 Da
Purity (QSC)≥99% HPLC
FormLyophilized powder
Storage−20 °C
View at QSC →

Overview

Semaglutide is a synthetic analog of GLP-1 (Glucagon-Like Peptide-1), a naturally occurring incretin hormone produced in the gut in response to food intake. The research compound version (distinct from pharmaceutical formulations) is used in preclinical metabolic research to study GLP-1 receptor signaling, appetite regulation, insulin secretion, and weight management mechanisms.

Mechanism of Action

GLP-1 receptor agonists mimic the effects of endogenous GLP-1, which is secreted by intestinal L-cells postprandially. The primary actions include stimulation of glucose-dependent insulin secretion, suppression of glucagon, delayed gastric emptying, and reduction of appetite signaling via hypothalamic GLP-1 receptors. The semaglutide modification incorporates a C18 fatty acid chain via a linker, enabling albumin binding and dramatically extending half-life compared to native GLP-1 (which has a half-life of approximately 2 minutes).

Research Applications

  • Obesity and energy balance studies in diet-induced obese mouse models
  • Beta cell function and insulin secretion dynamics research
  • Cardiovascular metabolic risk factor studies
  • Neurological effects of GLP-1 signaling — neuroprotection models
  • Comparison studies with other GLP-1 class peptides (liraglutide, tirzepatide)

Research Notes

Semaglutide for research is supplied as a lyophilized powder with ≥99% HPLC-verified purity. It is not approved for human use when sourced as a research compound. Researchers should differentiate between the pharmaceutical product (Ozempic/Wegovy) and the research-grade compound, which is intended solely for in vitro and animal model research.

Tirzepatide
GIP/GLP-1 Dual Agonist
TypeDual incretin receptor agonist
MW4813.5 Da
Purity (QSC)≥99% HPLC
ReceptorsGIP-R + GLP-1R
View at QSC →

Overview

Tirzepatide is a novel dual incretin receptor agonist that simultaneously activates both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 receptors. This dual mechanism distinguishes it from single-target GLP-1 agonists like semaglutide. Research on tirzepatide has focused heavily on its superior metabolic effects — studies in rodent models showed substantially greater fat mass reduction compared to selective GLP-1 agonists.

Dual Mechanism Research

The GIP receptor component is of particular scientific interest. While early research suggested GIP receptor agonism would be counterproductive in obesity (given that GIP promotes fat storage), tirzepatide's research profile challenges this assumption. The GIP component appears to work synergistically with GLP-1 signaling in adipose tissue and the brain, though the precise mechanism of this synergy is still being investigated. The research compound is invaluable for studying the differential contributions of each receptor pathway.

  • Superior fat mass reduction vs. GLP-1 monotherapy in preclinical models
  • GIP receptor biology and its role in energy homeostasis
  • Adipogenesis and adipose tissue remodeling studies
  • Pancreatic beta cell preservation research
  • Central nervous system appetite circuit studies
AOD-9604
Anti-Obesity Drug Fragment
TypeHGH fragment 176–191
MW1817.1 Da
OriginC-terminal hGH fragment
Purity (QSC)≥99% HPLC
View at QSC →

Overview

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH) comprising amino acids 176–191 of the C-terminal region. It was originally developed by Monash University researchers in Australia as a potential anti-obesity compound that could replicate the fat-burning properties of hGH without the growth-promoting and diabetogenic effects of the full hormone. Its selectivity for fat metabolism pathways — without affecting IGF-1 or insulin levels — makes it a valuable research tool.

Key Research Areas

  • Lipolysis stimulation via beta-3 adrenergic receptor pathways
  • Selective fat oxidation without anabolic growth hormone effects
  • Chondroprotective effects — studies in osteoarthritis models
  • Cartilage and bone metabolism research independent of fat-loss applications
  • Differentiation from full hGH in terms of IGF-1 axis interactions
How They Work

Metabolic Peptide Mechanisms Explained

Understanding how different classes of metabolic research peptides interact with human physiology — from incretin hormones to growth hormone fragments.

GLP-1 RECEPTOR AGONIST SIGNALING PATHWAY FOOD INTAKE Stimulus INTESTINAL L-CELL Secretes GLP-1 t½ = ~2 min GLP-1R ACTIVATION Pancreas · Brain GI tract · Heart ← Semaglutide mimics this ↑ INSULIN Glucose-dependent ↓ GLUCAGON Reduces hepatic glucose ↑ SATIETY Hypothalamic signaling METABOLIC IMPROVEMENT ↓ Body weight Additional: ↓ Gastric emptying · ↓ Food reward signaling · Cardioprotective effects (CNS)
PATHWAY — 01
GLP-1 Receptor Agonism
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone secreted by intestinal L-cells post-meal. GLP-1 receptor agonists like semaglutide mimic this signal, triggering insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and activating hypothalamic satiety circuits. The result is reduced caloric intake and improved glycemic control — mechanisms studied extensively in metabolic research models.
PATHWAY — 02
GIP/GLP-1 Dual Agonism
Tirzepatide represents a second generation of incretin research tools that simultaneously engage both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 receptors. GIP receptors are expressed in adipose tissue and the brain in addition to pancreatic beta cells. The dual activation produces metabolic effects that exceed GLP-1 monotherapy in preclinical models, though the precise synergistic mechanisms — particularly in central nervous system circuits — remain active research topics.
PATHWAY — 03
Lipolytic Peptide Fragments
AOD-9604 acts on beta-3 adrenergic receptors to stimulate lipolysis (the breakdown of stored fat). Unlike full hGH, it does not activate IGF-1 signaling, making it useful for isolating fat metabolism effects from anabolic growth hormone activity. The compound has been studied for its ability to promote fat oxidation in white adipose tissue while preserving lean mass — a key distinction in obesity research.
PATHWAY — 04
GH Secretagogues (CJC-1295 / Ipamorelin)
CJC-1295 is a GHRH (Growth Hormone Releasing Hormone) analog that stimulates the pituitary to secrete growth hormone in a pulsatile pattern. Ipamorelin is a selective GHRP (Growth Hormone Releasing Peptide) that triggers GH release via ghrelin receptor activation without elevating cortisol or prolactin. Together, they are studied for combined metabolic effects — specifically the relationship between GH pulsatility, fat metabolism, and lean mass preservation in aging and obesity models.
Quality Metrics

Purity Standards & Research Data

HPLC Purity — QSC Metabolic Range
95% 98% 99% 100% Semaglutide 99.3% Tirzepatide 99.1% AOD-9604 99.5% CJC-1295 99.4% Ipamorelin 99.6%
Avg Body Weight Reduction — Preclinical Models (Relative)
Tirzepatide ~22% Semaglutide ~16% CJC-1295 + Ipamorelin ~11% AOD-9604 ~8% Preclinical animal model data — not representative of human outcomes
Side-by-Side Reference

Weight Loss Peptide Comparison

Compound Class Primary Mechanism Key Research Focus MW QSC Stock
Semaglutide GLP-1 RA GLP-1 receptor agonism, insulin secretion, appetite suppression Obesity, T2D, cardiovascular metabolic risk 4113.6 Da In Stock
Tirzepatide GIP/GLP-1 Dual RA Dual incretin receptor activation, synergistic metabolic effects Superior fat mass reduction, T2D, adipose biology 4813.5 Da In Stock
AOD-9604 hGH Fragment Beta-3 adrenergic lipolysis, fat oxidation Selective fat metabolism, cartilage protection 1817.1 Da In Stock
CJC-1295 GHRH Analog Pituitary GH stimulation via GHRH receptors GH pulsatility, lean mass, fat metabolism 3367.9 Da In Stock
Ipamorelin GHRP / Ghrelin analog Selective GH release, no cortisol/prolactin elevation GH secretion, body composition, aging 711.9 Da In Stock
Research Digest

Metabolic Peptide Research Summaries

Semaglutide · Obesity Research
GLP-1 Agonism in Preclinical Obesity Models: A Decade of Data
Research spanning more than a decade in rodent models of diet-induced obesity has established GLP-1 receptor agonists as among the most potent metabolic research tools available. Key findings include dose-dependent reductions in food intake, preservation of lean mass during weight loss, and improvements in insulin sensitivity independent of weight change — pointing to direct pancreatic and hepatic effects beyond satiety alone.
Multiple authorsDiabetes, Obesity & Metabolism
Tirzepatide · Mechanism
Dual GIP/GLP-1 Agonism Outperforms GLP-1 Monotherapy in Rodent Obesity Models
Comparative studies between tirzepatide-class dual agonists and selective GLP-1 receptor agonists in high-fat diet mouse models consistently showed greater reductions in total fat mass with the dual agonist. This appears driven by the additive adipose tissue effects of GIP receptor activation combined with the central appetite effects of GLP-1 signaling — a finding that has reshaped thinking about the role of GIP in energy balance.
Coskun et al.Nature Metabolism
AOD-9604 · Lipolysis
The C-Terminal Fragment of hGH: Selective Lipolytic Activity Without Growth Effects
Early Monash University research established that the C-terminal fragment of hGH (residues 176–191, now known as AOD-9604) retains the fat-burning properties of full growth hormone while eliminating the diabetogenic and anabolic effects. This was demonstrated in both in vitro adipocyte cultures and obese mouse models, where AOD-9604 significantly increased fat oxidation rates without affecting IGF-1 levels or producing the glucose intolerance associated with full hGH administration.
Heffernan et al.American Journal of Physiology
CJC-1295 · GH Axis
Extended Half-Life GHRH Analogs and Their Effects on GH Pulsatility
CJC-1295's modification — incorporating drug affinity complex (DAC) technology — dramatically extends its half-life versus native GHRH by enabling albumin binding. Research showed that this produces sustained elevation of baseline GH and IGF-1 levels without abolishing the normal pulsatile GH release pattern. This pulsatility preservation is considered important for maintaining receptor sensitivity and avoiding the desensitization associated with continuous GH elevation.
Ionescu & FrohmanJournal of Clinical Endocrinology & Metabolism
GLP-1 · Central Nervous System
GLP-1 Receptors in the Brain: Beyond Appetite Suppression
GLP-1 receptors are expressed throughout the central nervous system, not only in the hypothalamic satiety circuits. Research has identified GLP-1R expression in regions governing reward, cognition, and stress response. This distribution has implications beyond weight research — GLP-1 agonists have shown neuroprotective properties in Alzheimer's and Parkinson's disease models, and are being studied for addiction behavior modulation, significantly expanding their research relevance.
Cork et al.British Journal of Pharmacology
Ipamorelin · Selectivity
Ipamorelin: The Case for Selective GH Secretagogues
Compared to earlier GHRPs (GHRP-2, GHRP-6), ipamorelin was identified as having superior selectivity — producing equivalent GH release without the increases in ACTH, cortisol, or prolactin seen with non-selective secretagogues. This selectivity makes it the preferred GHRP for research isolating GH-specific metabolic effects from broader neuroendocrine perturbations. Its clean receptor profile makes it valuable as a comparator compound in GH axis research.
Raun et al.European Journal of Endocrinology
Key Terms

Metabolic Peptide Glossary

GLP-1 (Glucagon-Like Peptide-1)
An incretin hormone secreted by intestinal L-cells in response to food intake. Stimulates insulin secretion, inhibits glucagon, slows gastric emptying, and promotes satiety via hypothalamic receptors. Native GLP-1 has a half-life of ~2 minutes due to DPP-4 enzyme degradation. Research analogs extend this significantly.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
The second major incretin hormone, secreted by K-cells in the small intestine. Long assumed to have primarily pro-lipogenic effects, GIP receptor agonism in the context of dual GIP/GLP-1 agonists (tirzepatide) has been shown to produce synergistic metabolic benefits, challenging earlier assumptions about its role in obesity.
Incretin Effect
The phenomenon whereby oral glucose intake stimulates greater insulin secretion than intravenous glucose at equivalent blood glucose levels. This amplification is mediated by GLP-1 and GIP. The incretin effect is significantly reduced in type 2 diabetes, making incretin-based research compounds particularly relevant to T2D research programs.
Lipolysis
The enzymatic hydrolysis of triglycerides into glycerol and free fatty acids. Occurs primarily in adipose tissue in response to energy demand. Stimulated by catecholamines (adrenaline, noradrenaline) via beta-adrenergic receptors, and suppressed by insulin. AOD-9604 promotes lipolysis via beta-3 adrenergic pathway activation.
GHRH (Growth Hormone Releasing Hormone)
A hypothalamic peptide that stimulates the anterior pituitary to secrete growth hormone. GHRH is released in a pulsatile fashion, creating the characteristic GH pulses — predominantly during slow-wave sleep. CJC-1295 is a synthetic GHRH analog with extended half-life due to albumin-binding modification.
GH Secretagogue
A compound that stimulates growth hormone secretion. Includes both GHRH analogs (like CJC-1295) and GHRPs/ghrelin analogs (like ipamorelin). These two classes work through distinct receptors and can produce synergistic GH release when combined in research protocols.
Receptor Agonist
A molecule that binds to and activates a receptor, producing a biological response similar to the endogenous ligand. GLP-1 receptor agonists like semaglutide mimic the action of native GLP-1 but with greater potency and much longer duration due to structural modifications that resist enzymatic degradation.
Lyophilized
Freeze-dried. Research peptides are supplied in lyophilized powder form for stability during storage and shipping. The process removes water by sublimation under vacuum, preserving peptide structure. Reconstitution with bacteriostatic water is required before use in research applications.
Sourcing Guide

How to Source Research-Grade Metabolic Peptides

STEP — 01
Confirm HPLC Purity
Research-grade metabolic peptides should meet ≥98% purity minimum — QSC Peptides consistently delivers ≥99%. Purity is verified by HPLC (High-Performance Liquid Chromatography) and published in the COA for each batch.
STEP — 02
STEP — 02
Request Mass Spec Confirmation
Identity confirmation via mass spectrometry (MS) or LC-MS/MS is essential for complex peptides like semaglutide and tirzepatide. The COA should confirm the molecular weight matches the theoretical value. QSC provides MS data on all products.
STEP — 03
Select Domestic Sourcing
USA-domestic fulfillment avoids customs inspection and cold-chain disruption. QSC Peptides ships from US, EU, UK, AU, and CA domestic warehouses with free shipping on all orders. Select the warehouse closest to your research location.
STEP — 04
Verify Research-Only Labeling
All legitimate research peptide suppliers label products "For Research Use Only — Not for Human Consumption." This is standard regulatory practice. QSC Peptides maintains this across all products. Avoid suppliers without this labeling.

Source Research-Grade Metabolic Peptides

Shop QSC Peptides →

⚠ FOR RESEARCH USE ONLY — All compounds referenced on this website are research chemicals intended for in vitro and animal model studies only. These are not FDA-approved for human use. This site does not provide medical advice. WeightLossPeptides.com is an independent educational resource and affiliate of QSC Peptides (qscpeptide.com). Always consult a licensed healthcare professional regarding any health-related matters.